This letter from CRAG (TB Community Research Advisors Group) and TAG was sent to Anne Whitaker, President, North America Pharmaceuticals of Sanofi US. It commends Sanofi for making this commitment to lower the price of rifapentine for Public Health Service…
TAG, CRAG, and the TB CAB issues urgent appeal for Otsuka to initiate its long overdue compassionate use program by the end of 2013.
167 Organizations and 513 Individuals Signed on to Letter to Secretary Sebelius on the Allowance of Co-pay Assistance in the ACA Health Plans
TAG and 134 other organizations sent this letter to underscore the need for a swift response from UNITAID to hepatitis C virus (HCV) coinfection; delays will cost lives and impede scale-up when more effective and tolerable therapies are available.
We are writing to express serious concern and dismay regarding the shutting down of the website for the Conference on Retroviruses and Opportunistic Infections (CROI).
A broad coalition of HIV/AIDS advocates and advocacy organizations urge patient groups to support the AllTrials Initiative.
TAG and Other Orgs Issued this letter to Gilead about TAF.
14 May 2013 Peer M. Schatz Chief Executive Officer and Managing Director QIAGEN Benelux B.V. Spoorstraat 50 5911 KJ Venlo The Netherlands Email: peer.schatz@qiagen.com RE: Marketing and Use of QuantiFERON-TB Gold for active TB in India and high TB burden…
Letter urging the company to reconsider its negative decision to provide free telmisartan (Micardis) and matching placebo to the AIDS Clinical Trials Group so that it may move forward with Study A5317.
Letter from TAG and civil society organizations undersigned grassroots civil society groups and non-governmental organizations asking for universal access to HCV voluntary testing and treatment.